🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Inflammatory Biomarkers in Ocular Surface in Primary Open Angle Glaucoma or Ocular Hypertension Under Topical Prostaglandins

Recruitingn/aAges 18 Years - 99 YearsAllInstituto Universitario de Oftalmobiología Aplica…
NCT05039684 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Glaucoma is a chronic optic neuropathy whose main modifiable risk factor is an abnormally elevated intraocular pressure. The aim of glaucoma treatment is to slow the progression of the disease by reducing intraocular pressure. Prostaglandin derivatives are the most effective topical drugs in reducing intraocular pressure (IOP). Among these, latanoprost was the first agent of this type to be approved for use in patients with glaucoma or ocular hypertension. These eye drops are available with and without preservatives. There are two commercial brands in our environment, Xalatan®, which contains 0.005% latanoprost and 0.2 mg/ml benzalkonium chloride (BAK) and Monoprost®, which contains the same amount of latanoprost but does not carry a preservative. The prostaglandin analog with a lower concentration of active ingredient available in Spain without preservative is tafluprost 0.0015%, comm

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients with primary open angle glaucoma or ocular hypertension as defined in Early Manifest Glaucoma Trial * \> 18 years old * Signed informed consent * 3 or more months under monotherapy treatment with tafluprost 0.0015%, latanoprost 0.005% with BAK 0.2mg/ml or latanoprost 0.005%. * Untreated patients with ocular hypertension must be treatment naïve for the pathology. * No presence or history of previous ocular diseases other than glaucoma or ocular hypertension, started before the use of hypotensive medication. Exclusion Criteria: * Ocular surgery in the previous 6 months. * Any ocular surface disease not related to inclusion criteria or related issues active within the last 6 months. * Any topical treatment other than the evaluated in this study in the last 3 months. * In case of artificial teardrops use, only non conservative ones are allowed, with no more than 4 times per day use, and treatment must be suspended 5 days before inclusion. * Use of contact lenses in the las 4 weeks. * Any mental or physical disease that may prevent performing the required tests for the study.
💊

What it tests

  • Not listed
📍

Where

1 site
IOBA
Valladolid, Spain
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy